Global Idiopathic Pulmonary Fibrosis (IPF) Market 2024-2028

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $2,500	174 Pages	TechNavio	July, 2024	INF19115334

Best Price Guarantee
Price	from $2,500
Length	174 Pages
Publisher	TechNavio
Published Date	July, 2024
SKU	INF19115334

Global Idiopathic Pulmonary Fibrosis (IPF) Market 2024-2028

Global Idiopathic Pulmonary Fibrosis (IPF) Market 2024-2028

The idiopathic pulmonary fibrosis (IPF) market is forecasted to grow by USD 1473.2 mn during 2023-2028, accelerating at a CAGR of 6.78% during the forecast period. The report on the idiopathic pulmonary fibrosis (IPF) market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of respiratory diseases, growing geriatric population, and increase in number of smokers.

Technavio's idiopathic pulmonary fibrosis (IPF) market is segmented as below:

By Route Of Administration
Oral
Parenteral
By Drug Class
Systemic corticosteroids
Immunosuppressants
Tyrosine kinase inhibitors
Anti-fibrotic agents
By Geographical Landscape
North America
Europe
Asia
Rest of World (ROW)

This study identifies the increase in drug pipeline for IPF as one of the prime reasons driving the idiopathic pulmonary fibrosis (IPF) market growth during the next few years. Also, development of novel drugs for treatment of IPF and emergence of new patterns of IPF will lead to sizable demand in the market.

The report on the idiopathic pulmonary fibrosis (IPF) market covers the following areas:

Idiopathic pulmonary fibrosis (IPF) market sizing
Idiopathic pulmonary fibrosis (IPF) market forecast
Idiopathic pulmonary fibrosis (IPF) market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading idiopathic pulmonary fibrosis (IPF) market vendors that include Alembic Pharmaceuticals Ltd., AstraZeneca PLC, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Celix Pharma Ltd., Cipla Inc., Daewoong Pharmaceutical Co. Ltd., F. Hoffmann La Roche Ltd., FibroGen Inc., Galapagos NV, Galecto Inc., GNI Group Ltd., Horizon Therapeutics PLC, Intas Pharmaceuticals Ltd., Jubilant Pharmova Ltd., Liminal BioSciences Inc., MediciNova Inc., Merck and Co. Inc., Mission Therapeutics, Novartis AG, SHIONOGI Co. Ltd., and United Therapeutics Corp.. Also, the idiopathic pulmonary fibrosis (IPF) market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

1 Executive Summary: 1.1 Market overview; Executive Summary - Chart on Market Overview; Executive Summary - Data Table on Market Overview; Executive Summary - Chart on Global Market Characteristics; Executive Summary - Chart on Market By Geographical Landscape; Executive Summary - Chart on Market Segmentation by Route of Administration; Executive Summary - Chart on Market Segmentation by Drug Class; Executive Summary - Chart on Incremental Growth; Executive Summary - Data Table on Incremental Growth; Executive Summary - Chart on Company Market Positioning
2 Market Landscape: 2.1 Market ecosystem; Parent Market; Data Table on - Parent Market; 2.2 Market characteristics; Market characteristics analysis; 2.3 Value chain analysis; Value Chain Analysis
3 Market Sizing: 3.1 Market definition; Offerings of companies included in the market definition; 3.2 Market segment analysis; Market segments; 3.3 Market size 2023; 3.4 Market outlook: Forecast for 2023-2028; Chart on Global - Market size and forecast 2023-2028 ($ million); Data Table on Global - Market size and forecast 2023-2028 ($ million); Chart on Global Market: Year-over-year growth 2023-2028 (%); Data Table on Global Market: Year-over-year growth 2023-2028 (%)
4 Historic Market Size: 4.1 Global Idiopathic Pulmonary Fibrosis (IPF) Market 2018 - 2022; Historic Market Size - Data Table on Global Idiopathic Pulmonary Fibrosis (IPF) Market 2018 - 2022 ($ million); 4.2 Route of Administration segment analysis 2018 - 2022; Historic Market Size - Route of Administration Segment 2018 - 2022 ($ million); 4.3 Drug Class segment analysis 2018 - 2022; Historic Market Size - Drug Class Segment 2018 - 2022 ($ million); 4.4 Geography segment analysis 2018 - 2022; Historic Market Size - Geography Segment 2018 - 2022 ($ million); 4.5 Country segment analysis 2018 - 2022; Historic Market Size - Country Segment 2018 - 2022 ($ million)
5 Five Forces Analysis: 5.1 Five forces summary; Five forces analysis - Comparison between 2023 and 2028; 5.2 Bargaining power of buyers; Bargaining power of buyers - Impact of key factors 2023 and 2028; 5.3 Bargaining power of suppliers; Bargaining power of suppliers - Impact of key factors in 2023 and 2028; 5.4 Threat of new entrants; Threat of new entrants - Impact of key factors in 2023 and 2028; 5.5 Threat of substitutes; Threat of substitutes - Impact of key factors in 2023 and 2028; 5.6 Threat of rivalry; Threat of rivalry - Impact of key factors in 2023 and 2028; 5.7 Market condition; Chart on Market condition - Five forces 2023 and 2028
6 Market Segmentation by Route of Administration: 6.1 Market segments; Chart on Route of Administration - Market share 2023-2028 (%); Data Table on Route of Administration - Market share 2023-2028 (%); 6.2 Comparison by Route of Administration; Chart on Comparison by Route of Administration; Data Table on Comparison by Route of Administration; 6.3 Oral - Market size and forecast 2023-2028; Chart on Oral - Market size and forecast 2023-2028 ($ million); Data Table on Oral - Market size and forecast 2023-2028 ($ million); Chart on Oral - Year-over-year growth 2023-2028 (%); Data Table on Oral - Year-over-year growth 2023-2028 (%); 6.4 Parenteral - Market size and forecast 2023-2028; Chart on Parenteral - Market size and forecast 2023-2028 ($ million); Data Table on Parenteral - Market size and forecast 2023-2028 ($ million); Chart on Parenteral - Year-over-year growth 2023-2028 (%); Data Table on Parenteral - Year-over-year growth 2023-2028 (%); 6.5 Market opportunity by Route of Administration; Market opportunity by Route of Administration ($ million); Data Table on Market opportunity by Route of Administration ($ million)
7 Market Segmentation by Drug Class: 7.1 Market segments; Chart on Drug Class - Market share 2023-2028 (%); Data Table on Drug Class - Market share 2023-2028 (%); 7.2 Comparison by Drug Class; Chart on Comparison by Drug Class; Data Table on Comparison by Drug Class; 7.3 Systemic corticosteroids - Market size and forecast 2023-2028; Chart on Systemic corticosteroids - Market size and forecast 2023-2028 ($ million); Data Table on Systemic corticosteroids - Market size and forecast 2023-2028 ($ million); Chart on Systemic corticosteroids - Year-over-year growth 2023-2028 (%); Data Table on Systemic corticosteroids - Year-over-year growth 2023-2028 (%); 7.4 Immunosuppressants - Market size and forecast 2023-2028; Chart on Immunosuppressants - Market size and forecast 2023-2028 ($ million); Data Table on Immunosuppressants - Market size and forecast 2023-2028 ($ million); Chart on Immunosuppressants - Year-over-year growth 2023-2028 (%); Data Table on Immunosuppressants - Year-over-year growth 2023-2028 (%); 7.5 Tyrosine kinase inhibitors - Market size and forecast 2023-2028; Chart on Tyrosine kinase inhibitors - Market size and forecast 2023-2028 ($ million); Data Table on Tyrosine kinase inhibitors - Market size and forecast 2023-2028 ($ million); Chart on Tyrosine kinase inhibitors - Year-over-year growth 2023-2028 (%); Data Table on Tyrosine kinase inhibitors - Year-over-year growth 2023-2028 (%); 7.6 Anti-fibrotic agents - Market size and forecast 2023-2028; Chart on Anti-fibrotic agents - Market size and forecast 2023-2028 ($ million); Data Table on Anti-fibrotic agents - Market size and forecast 2023-2028 ($ million); Chart on Anti-fibrotic agents - Year-over-year growth 2023-2028 (%); Data Table on Anti-fibrotic agents - Year-over-year growth 2023-2028 (%); 7.7 Market opportunity by Drug Class; Market opportunity by Drug Class ($ million); Data Table on Market opportunity by Drug Class ($ million)
8 Customer Landscape: 8.1 Customer landscape overview; Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape: 9.1 Geographic segmentation; Chart on Market share By Geographical Landscape 2023-2028 (%); Data Table on Market share By Geographical Landscape 2023-2028 (%); 9.2 Geographic comparison; Chart on Geographic comparison; Data Table on Geographic comparison; 9.3 North America - Market size and forecast 2023-2028; Chart on North America - Market size and forecast 2023-2028 ($ million); Data Table on North America - Market size and forecast 2023-2028 ($ million); Chart on North America - Year-over-year growth 2023-2028 (%); Data Table on North America - Year-over-year growth 2023-2028 (%); 9.4 Europe - Market size and forecast 2023-2028; Chart on Europe - Market size and forecast 2023-2028 ($ million); Data Table on Europe - Market size and forecast 2023-2028 ($ million); Chart on Europe - Year-over-year growth 2023-2028 (%); Data Table on Europe - Year-over-year growth 2023-2028 (%); 9.5 Asia - Market size and forecast 2023-2028; Chart on Asia - Market size and forecast 2023-2028 ($ million); Data Table on Asia - Market size and forecast 2023-2028 ($ million); Chart on Asia - Year-over-year growth 2023-2028 (%); Data Table on Asia - Year-over-year growth 2023-2028 (%); 9.6 Rest of World (ROW) - Market size and forecast 2023-2028; Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million); Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million); Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); 9.7 US - Market size and forecast 2023-2028; Chart on US - Market size and forecast 2023-2028 ($ million); Data Table on US - Market size and forecast 2023-2028 ($ million); Chart on US - Year-over-year growth 2023-2028 (%); Data Table on US - Year-over-year growth 2023-2028 (%); 9.8 China - Market size and forecast 2023-2028; Chart on China - Market size and forecast 2023-2028 ($ million); Data Table on China - Market size and forecast 2023-2028 ($ million); Chart on China - Year-over-year growth 2023-2028 (%); Data Table on China - Year-over-year growth 2023-2028 (%); 9.9 Japan - Market size and forecast 2023-2028; Chart on Japan - Market size and forecast 2023-2028 ($ million); Data Table on Japan - Market size and forecast 2023-2028 ($ million); Chart on Japan - Year-over-year growth 2023-2028 (%); Data Table on Japan - Year-over-year growth 2023-2028 (%); 9.10 Germany - Market size and forecast 2023-2028; Chart on Germany - Market size and forecast 2023-2028 ($ million); Data Table on Germany - Market size and forecast 2023-2028 ($ million); Chart on Germany - Year-over-year growth 2023-2028 (%); Data Table on Germany - Year-over-year growth 2023-2028 (%); 9.11 UK - Market size and forecast 2023-2028; Chart on UK - Market size and forecast 2023-2028 ($ million); Data Table on UK - Market size and forecast 2023-2028 ($ million); Chart on UK - Year-over-year growth 2023-2028 (%); Data Table on UK - Year-over-year growth 2023-2028 (%); 9.12 Market opportunity By Geographical Landscape; Market opportunity By Geographical Landscape ($ million); Data Tables on Market opportunity By Geographical Landscape ($ million)
10 Drivers, Challenges, and Opportunity/Restraints: 10.1 Market drivers; 10.2 Market challenges; 10.3 Impact of drivers and challenges; Impact of drivers and challenges in 2023 and 2028; 10.4 Market opportunities/restraints
11 Competitive Landscape: 11.1 Overview; 11.2 Competitive Landscape; Overview on criticality of inputs and factors of differentiation; 11.3 Landscape disruption; Overview on factors of disruption; 11.4 Industry risks; Impact of key risks on business
12 Competitive Analysis: 12.1 Companies profiled; Companies covered; 12.2 Market positioning of companies; Matrix on companies position and classification; 12.3 AstraZeneca Plc; AstraZeneca Plc - Overview; AstraZeneca Plc - Product / Service; AstraZeneca Plc - Key news; AstraZeneca Plc - Key offerings; 12.4 Boehringer Ingelheim International GmbH; Boehringer Ingelheim International GmbH - Overview; Boehringer Ingelheim International GmbH - Product / Service; Boehringer Ingelheim International GmbH - Key news; Boehringer Ingelheim International GmbH - Key offerings; 12.5 Bristol Myers Squibb Co.; Bristol Myers Squibb Co. - Overview; Bristol Myers Squibb Co. - Product / Service; Bristol Myers Squibb Co. - Key news; Bristol Myers Squibb Co. - Key offerings; 12.6 Cipla Inc.; Cipla Inc. - Overview; Cipla Inc. - Business segments; Cipla Inc. - Key news; Cipla Inc. - Key offerings; Cipla Inc. - Segment focus; 12.7 F. Hoffmann La Roche Ltd.; F. Hoffmann La Roche Ltd. - Overview; F. Hoffmann La Roche Ltd. - Business segments; F. Hoffmann La Roche Ltd. - Key news; F. Hoffmann La Roche Ltd. - Key offerings; F. Hoffmann La Roche Ltd. - Segment focus; 12.8 FibroGen Inc.; FibroGen Inc. - Overview; FibroGen Inc. - Product / Service; FibroGen Inc. - Key offerings; 12.9 Galapagos NV; Galapagos NV - Overview; Galapagos NV - Product / Service; Galapagos NV - Key offerings; 12.10 GNI Group Ltd.; GNI Group Ltd. - Overview; GNI Group Ltd. - Product / Service; GNI Group Ltd. - Key offerings; 12.11 Horizon Therapeutics Plc; Horizon Therapeutics Plc - Overview; Horizon Therapeutics Plc - Product / Service; Horizon Therapeutics Plc - Key offerings; 12.12 Jubilant Pharmova Ltd.; Jubilant Pharmova Ltd. - Overview; Jubilant Pharmova Ltd. - Business segments; Jubilant Pharmova Ltd. - Key news; Jubilant Pharmova Ltd. - Key offerings; Jubilant Pharmova Ltd. - Segment focus; 12.13 Liminal BioSciences Inc.; Liminal BioSciences Inc. - Overview; Liminal BioSciences Inc. - Product / Service; Liminal BioSciences Inc. - Key offerings; 12.14 MediciNova Inc.; MediciNova Inc. - Overview; MediciNova Inc. - Product / Service; MediciNova Inc. - Key offerings; 12.15 Novartis AG; Novartis AG - Overview; Novartis AG - Business segments; Novartis AG - Key news; Novartis AG - Key offerings; Novartis AG - Segment focus; 12.16 SHIONOGI Co. Ltd.; SHIONOGI Co. Ltd. - Overview; SHIONOGI Co. Ltd. - Product / Service; SHIONOGI Co. Ltd. - Key offerings; 12.17 United Therapeutics Corp.; United Therapeutics Corp. - Overview; United Therapeutics Corp. - Product / Service; United Therapeutics Corp. - Key offerings
13 Appendix: 13.1 Scope of the report; 13.2 Inclusions and exclusions checklist; Inclusions checklist; Exclusions checklist; 13.3 Currency conversion rates for US$; Currency conversion rates for US$; 13.4 Research methodology; Research methodology; 13.5 Data procurement; Information sources; 13.6 Data validation; Data validation; 13.7 Validation techniques employed for market sizing; Validation techniques employed for market sizing; 13.8 Data synthesis; Data synthesis; 13.9 360 degree market analysis; 360 degree market analysis; 13.10 List of abbreviations; List of abbreviations; Exhibits:; Exhibits1: Executive Summary - Chart on Market Overview; Exhibits2: Executive Summary - Data Table on Market Overview; Exhibits3: Executive Summary - Chart on Global Market Characteristics; Exhibits4: Executive Summary - Chart on Market By Geographical Landscape; Exhibits5: Executive Summary - Chart on Market Segmentation by Route of Administration; Exhibits6: Executive Summary - Chart on Market Segmentation by Drug Class; Exhibits7: Executive Summary - Chart on Incremental Growth; Exhibits8: Executive Summary - Data Table on Incremental Growth; Exhibits9: Executive Summary - Chart on Company Market Positioning; Exhibits10: Parent Market; Exhibits11: Data Table on - Parent Market; Exhibits12: Market characteristics analysis; Exhibits13: Value Chain Analysis; Exhibits14: Offerings of companies included in the market definition; Exhibits15: Market segments; Exhibits16: Chart on Global - Market size and forecast 2023-2028 ($ million); Exhibits17: Data Table on Global - Market size and forecast 2023-2028 ($ million); Exhibits18: Chart on Global Market: Year-over-year growth 2023-2028 (%); Exhibits19: Data Table on Global Market: Year-over-year growth 2023-2028 (%); Exhibits20: Historic Market Size - Data Table on Global Idiopathic Pulmonary Fibrosis (IPF) Market 2018 - 2022 ($ million); Exhibits21: Historic Market Size - Route of Administration Segment 2018 - 2022 ($ million); Exhibits22: Historic Market Size - Drug Class Segment 2018 - 2022 ($ million); Exhibits23: Historic Market Size - Geography Segment 2018 - 2022 ($ million); Exhibits24: Historic Market Size - Country Segment 2018 - 2022 ($ million); Exhibits25: Five forces analysis - Comparison between 2023 and 2028; Exhibits26: Bargaining power of buyers - Impact of key factors 2023 and 2028; Exhibits27: Bargaining power of suppliers - Impact of key factors in 2023 and 2028; Exhibits28: Threat of new entrants - Impact of key factors in 2023 and 2028; Exhibits29: Threat of substitutes - Impact of key factors in 2023 and 2028; Exhibits30: Threat of rivalry - Impact of key factors in 2023 and 2028; Exhibits31: Chart on Market condition - Five forces 2023 and 2028; Exhibits32: Chart on Route of Administration - Market share 2023-2028 (%); Exhibits33: Data Table on Route of Administration - Market share 2023-2028 (%); Exhibits34: Chart on Comparison by Route of Administration; Exhibits35: Data Table on Comparison by Route of Administration; Exhibits36: Chart on Oral - Market size and forecast 2023-2028 ($ million); Exhibits37: Data Table on Oral - Market size and forecast 2023-2028 ($ million); Exhibits38: Chart on Oral - Year-over-year growth 2023-2028 (%); Exhibits39: Data Table on Oral - Year-over-year growth 2023-2028 (%); Exhibits40: Chart on Parenteral - Market size and forecast 2023-2028 ($ million); Exhibits41: Data Table on Parenteral - Market size and forecast 2023-2028 ($ million); Exhibits42: Chart on Parenteral - Year-over-year growth 2023-2028 (%); Exhibits43: Data Table on Parenteral - Year-over-year growth 2023-2028 (%); Exhibits44: Market opportunity by Route of Administration ($ million); Exhibits45: Data Table on Market opportunity by Route of Administration ($ million); Exhibits46: Chart on Drug Class - Market share 2023-2028 (%); Exhibits47: Data Table on Drug Class - Market share 2023-2028 (%); Exhibits48: Chart on Comparison by Drug Class; Exhibits49: Data Table on Comparison by Drug Class; Exhibits50: Chart on Systemic corticosteroids - Market size and forecast 2023-2028 ($ million); Exhibits51: Data Table on Systemic corticosteroids - Market size and forecast 2023-2028 ($ million); Exhibits52: Chart on Systemic corticosteroids - Year-over-year growth 2023-2028 (%); Exhibits53: Data Table on Systemic corticosteroids - Year-over-year growth 2023-2028 (%); Exhibits54: Chart on Immunosuppressants - Market size and forecast 2023-2028 ($ million); Exhibits55: Data Table on Immunosuppressants - Market size and forecast 2023-2028 ($ million); Exhibits56: Chart on Immunosuppressants - Year-over-year growth 2023-2028 (%); Exhibits57: Data Table on Immunosuppressants - Year-over-year growth 2023-2028 (%); Exhibits58: Chart on Tyrosine kinase inhibitors - Market size and forecast 2023-2028 ($ million); Exhibits59: Data Table on Tyrosine kinase inhibitors - Market size and forecast 2023-2028 ($ million); Exhibits60: Chart on Tyrosine kinase inhibitors - Year-over-year growth 2023-2028 (%); Exhibits61: Data Table on Tyrosine kinase inhibitors - Year-over-year growth 2023-2028 (%); Exhibits62: Chart on Anti-fibrotic agents - Market size and forecast 2023-2028 ($ million); Exhibits63: Data Table on Anti-fibrotic agents - Market size and forecast 2023-2028 ($ million); Exhibits64: Chart on Anti-fibrotic agents - Year-over-year growth 2023-2028 (%); Exhibits65: Data Table on Anti-fibrotic agents - Year-over-year growth 2023-2028 (%); Exhibits66: Market opportunity by Drug Class ($ million); Exhibits67: Data Table on Market opportunity by Drug Class ($ million); Exhibits68: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria; Exhibits69: Chart on Market share By Geographical Landscape 2023-2028 (%); Exhibits70: Data Table on Market share By Geographical Landscape 2023-2028 (%); Exhibits71: Chart on Geographic comparison; Exhibits72: Data Table on Geographic comparison; Exhibits73: Chart on North America - Market size and forecast 2023-2028 ($ million); Exhibits74: Data Table on North America - Market size and forecast 2023-2028 ($ million); Exhibits75: Chart on North America - Year-over-year growth 2023-2028 (%); Exhibits76: Data Table on North America - Year-over-year growth 2023-2028 (%); Exhibits77: Chart on Europe - Market size and forecast 2023-2028 ($ million); Exhibits78: Data Table on Europe - Market size and forecast 2023-2028 ($ million); Exhibits79: Chart on Europe - Year-over-year growth 2023-2028 (%); Exhibits80: Data Table on Europe - Year-over-year growth 2023-2028 (%); Exhibits81: Chart on Asia - Market size and forecast 2023-2028 ($ million); Exhibits82: Data Table on Asia - Market size and forecast 2023-2028 ($ million); Exhibits83: Chart on Asia - Year-over-year growth 2023-2028 (%); Exhibits84: Data Table on Asia - Year-over-year growth 2023-2028 (%); Exhibits85: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million); Exhibits86: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million); Exhibits87: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); Exhibits88: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); Exhibits89: Chart on US - Market size and forecast 2023-2028 ($ million); Exhibits90: Data Table on US - Market size and forecast 2023-2028 ($ million); Exhibits91: Chart on US - Year-over-year growth 2023-2028 (%); Exhibits92: Data Table on US - Year-over-year growth 2023-2028 (%); Exhibits93: Chart on China - Market size and forecast 2023-2028 ($ million); Exhibits94: Data Table on China - Market size and forecast 2023-2028 ($ million); Exhibits95: Chart on China - Year-over-year growth 2023-2028 (%); Exhibits96: Data Table on China - Year-over-year growth 2023-2028 (%); Exhibits97: Chart on Japan - Market size and forecast 2023-2028 ($ million); Exhibits98: Data Table on Japan - Market size and forecast 2023-2028 ($ million); Exhibits99: Chart on Japan - Year-over-year growth 2023-2028 (%); Exhibits100: Data Table on Japan - Year-over-year growth 2023-2028 (%); Exhibits101: Chart on Germany - Market size and forecast 2023-2028 ($ million); Exhibits102: Data Table on Germany - Market size and forecast 2023-2028 ($ million); Exhibits103: Chart on Germany - Year-over-year growth 2023-2028 (%); Exhibits104: Data Table on Germany - Year-over-year growth 2023-2028 (%); Exhibits105: Chart on UK - Market size and forecast 2023-2028 ($ million); Exhibits106: Data Table on UK - Market size and forecast 2023-2028 ($ million); Exhibits107: Chart on UK - Year-over-year growth 2023-2028 (%); Exhibits108: Data Table on UK - Year-over-year growth 2023-2028 (%); Exhibits109: Market opportunity By Geographical Landscape ($ million); Exhibits110: Data Tables on Market opportunity By Geographical Landscape ($ million); Exhibits111: Impact of drivers and challenges in 2023 and 2028; Exhibits112: Overview on criticality of inputs and factors of differentiation; Exhibits113: Overview on factors of disruption; Exhibits114: Impact of key risks on business; Exhibits115: Companies covered; Exhibits116: Matrix on companies position and classification; Exhibits117: AstraZeneca Plc - Overview; Exhibits118: AstraZeneca Plc - Product / Service; Exhibits119: AstraZeneca Plc - Key news; Exhibits120: AstraZeneca Plc - Key offerings; Exhibits121: Boehringer Ingelheim International GmbH - Overview; Exhibits122: Boehringer Ingelheim International GmbH - Product / Service; Exhibits123: Boehringer Ingelheim International GmbH - Key news; Exhibits124: Boehringer Ingelheim International GmbH - Key offerings; Exhibits125: Bristol Myers Squibb Co. - Overview; Exhibits126: Bristol Myers Squibb Co. - Product / Service; Exhibits127: Bristol Myers Squibb Co. - Key news; Exhibits128: Bristol Myers Squibb Co. - Key offerings; Exhibits129: Cipla Inc. - Overview; Exhibits130: Cipla Inc. - Business segments; Exhibits131: Cipla Inc. - Key news; Exhibits132: Cipla Inc. - Key offerings; Exhibits133: Cipla Inc. - Segment focus; Exhibits134: F. Hoffmann La Roche Ltd. - Overview; Exhibits135: F. Hoffmann La Roche Ltd. - Business segments; Exhibits136: F. Hoffmann La Roche Ltd. - Key news; Exhibits137: F. Hoffmann La Roche Ltd. - Key offerings; Exhibits138: F. Hoffmann La Roche Ltd. - Segment focus; Exhibits139: FibroGen Inc. - Overview; Exhibits140: FibroGen Inc. - Product / Service; Exhibits141: FibroGen Inc. - Key offerings; Exhibits142: Galapagos NV - Overview; Exhibits143: Galapagos NV - Product / Service; Exhibits144: Galapagos NV - Key offerings; Exhibits145: GNI Group Ltd. - Overview; Exhibits146: GNI Group Ltd. - Product / Service; Exhibits147: GNI Group Ltd. - Key offerings; Exhibits148: Horizon Therapeutics Plc - Overview; Exhibits149: Horizon Therapeutics Plc - Product / Service; Exhibits150: Horizon Therapeutics Plc - Key offerings; Exhibits151: Jubilant Pharmova Ltd. - Overview; Exhibits152: Jubilant Pharmova Ltd. - Business segments; Exhibits153: Jubilant Pharmova Ltd. - Key news; Exhibits154: Jubilant Pharmova Ltd. - Key offerings; Exhibits155: Jubilant Pharmova Ltd. - Segment focus; Exhibits156: Liminal BioSciences Inc. - Overview; Exhibits157: Liminal BioSciences Inc. - Product / Service; Exhibits158: Liminal BioSciences Inc. - Key offerings; Exhibits159: MediciNova Inc. - Overview; Exhibits160: MediciNova Inc. - Product / Service; Exhibits161: MediciNova Inc. - Key offerings; Exhibits162: Novartis AG - Overview; Exhibits163: Novartis AG - Business segments; Exhibits164: Novartis AG - Key news; Exhibits165: Novartis AG - Key offerings; Exhibits166: Novartis AG - Segment focus; Exhibits167: SHIONOGI Co. Ltd. - Overview; Exhibits168: SHIONOGI Co. Ltd. - Product / Service; Exhibits169: SHIONOGI Co. Ltd. - Key offerings; Exhibits170: United Therapeutics Corp. - Overview; Exhibits171: United Therapeutics Corp. - Product / Service; Exhibits172: United Therapeutics Corp. - Key offerings; Exhibits173: Inclusions checklist; Exhibits174: Exclusions checklist; Exhibits175: Currency conversion rates for US$; Exhibits176: Research methodology; Exhibits177: Information sources; Exhibits178: Data validation; Exhibits179: Validation techniques employed for market sizing; Exhibits180: Data synthesis; Exhibits181: 360 degree market analysis; Exhibits182: List of abbreviations